# Interference in Macrophage Balance (M1/M2): The Mechanism of Action Responsible for the Anti-Inflammatory Effect of a Fluorophenyl-Substituted Imidazole

**Authors:** Julia Salvan da Rosa, Eduarda Talita Bramorski Mohr, Tainá Larissa Lubschinski, Guilherme Nicácio Vieira, Thais Andreia Rossa, Marcus Mandolesi Sá, Eduardo Monguilhott Dalmarco

PMC · DOI: 10.1155/2024/9528976 · 2024-02-17

## TL;DR

This paper shows that a fluorophenyl-imidazole compound reduces inflammation by shifting macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state.

## Contribution

The study identifies fluorophenyl-imidazole as a novel compound with immunomodulatory effects that repolarize macrophages.

## Key findings

- Fluorophenyl-imidazole reduces M1 macrophage markers like TNF-α, IL-6, and iNOS.
- The compound increases M2 macrophage markers such as IL-4, IL-13, and arginase-1.
- It induces macrophage repolarization to M2a without requiring LPS stimulation.

## Abstract

Traditionally, the treatment of inflammatory conditions has focused on the inhibition of inflammatory mediator production; however, many conditions are refractory to this classical approach. Recently, an alternative has been presented by researchers to solve this problem: The immunomodulation of cells closely related to inflammation. Hence, macrophages, a critical key in both innate and acquired immunity, have been presented as an alternative target for the development of new medicines. In this work, we tested the fluorophenyl-imidazole for its anti-inflammatory activity and possible immunomodulatory effect on RAW 264.7 macrophages. We also evaluated the anti-inflammatory effect of the compound, and the macrophage repolarization to M2 was confirmed by the ability of the compound to reduce the M1 markers TNF-α, IL-6, MCP-1, IL-12p70, IFN-γ, and TLR4, the high levels of p65 phosphorylated, iNOS and COX-2 mRNA expression, and the fact that the compound was not able to induce the production of M1 markers when used in macrophages without lipopolysaccharide (LPS) stimulation. Moreover, fluorophenyl-imidazole had the ability to increase the M2 markers IL-4, IL-13, CD206, apoptosis and phagocytosis levels, arginase-1, and FIZZ-1 mRNA expression before LPS stimulation. Similarly, it was also able to induce the production of these same M2 markers in macrophages without being induced with LPS. These results reinforce the affirmation that the fluorophenyl-imidazole has an important anti-inflammatory effect and demonstrates that this effect is due to immunomodulatory activity, having the ability to trigger a repolarization of macrophages from M1 to M2a. These facts suggest that this molecule could be used as an alternative scaffold for the development of a new medicine to treat inflammatory conditions, where the anti-inflammatory and proregenerative properties of M2a macrophages are desired.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], IL6 (interleukin 6) [NCBI Gene 3569], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], IFNG (interferon gamma) [NCBI Gene 3458], TLR4 (toll like receptor 4) [NCBI Gene 7099], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], IL4 (interleukin 4) [NCBI Gene 3565], IL13 (interleukin 13) [NCBI Gene 3596], MRC1 (mannose receptor C-type 1) [NCBI Gene 4360], Arg1 (arginase 1) [NCBI Gene 100750727], RETNLB (resistin like beta) [NCBI Gene 84666]
- **Chemicals:** fluorophenyl-imidazole (PubChem CID 140967342)

## Full-text entities

- **Genes:** IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, ARG1 (arginase 1) [NCBI Gene 383], IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, RETNLB (resistin like beta) [NCBI Gene 84666] {aka FIZZ1, FIZZ2, HXCP2, RELM-beta, RELMb, RELMbeta}
- **Diseases:** Inflammatory (MESH:D007249)
- **Chemicals:** Fluorophenyl-Substituted Imidazole (-), LPS (MESH:D008070)
- **Cell lines:** RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10894048/full.md

---
Source: https://tomesphere.com/paper/PMC10894048